Mingdong Huang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3055021/publications.pdf

Version: 2024-02-01

198	8,131	57758	58581
papers	citations	44 h-index	82 g-index

208	208	208	10024
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Expanding the applications of photodynamic therapyâ€"tooth bleaching. Clinical Oral Investigations, 2022, 26, 2175-2186.	3.0	6
2	Vascular thiol isomerases: Structures, regulatory mechanisms, and inhibitor development. Drug Discovery Today, 2022, 27, 626-635.	6.4	6
3	Structure-based molecular insights into matrix metalloproteinase inhibitors in cancer treatments. Future Medicinal Chemistry, 2022, 14, 35-51.	2.3	3
4	Enhanced clot lysis by a single point mutation in a reteplase variant. British Journal of Haematology, 2022, 196, 1076-1085.	2.5	3
5	A Clotâ€Homing Nearâ€Infrared Probe for In Vivo Imaging of Murine Thromboembolic Models. Advanced Healthcare Materials, 2022, 11, e2102213.	7.6	3
6	A versatile insertion point on albumin to accommodate peptides and maintain their activities. International Journal of Biological Macromolecules, 2022, 205, 49-54.	7.5	2
7	Crystal structure and cellular functions of uPAR dimer. Nature Communications, 2022, 13, 1665.	12.8	8
8	Flavonoids as Protein Disulfide Isomerase Inhibitors: Key Molecular and Structural Features for the Interaction. Journal of Agricultural and Food Chemistry, 2022, 70, 4475-4483.	5.2	8
9	Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA). Journal of Medicinal Chemistry, 2022, 65, 1933-1945.	6.4	5
10	Functionalized zinc oxide microparticles for improving the antimicrobial effects of skin-care products and wound-care medicines. , 2022, 135, 212728.		7
11	Identification of Antithrombotic Natural Products Targeting the Major Substrate Binding Pocket of Protein Disulfide Isomerase. Journal of Natural Products, 2022, 85, 1332-1339.	3.0	3
12	Orally delivered rutin in lipid-based nano-formulation exerts strong antithrombotic effects by protein disulfide isomerase inhibition. Drug Delivery, 2022, 29, 1824-1835.	5.7	7
13	Crystallographic analysis of interaction between cisplatin and human serum albumin: Effect of fatty acid. International Journal of Biological Macromolecules, 2022, 216, 172-178.	7.5	5
14	A strategy for enhanced tumor targeting of photodynamic therapy based on Escherichia coli-driven drug delivery system. Science China Materials, 2021, 64, 232-240.	6.3	9
15	Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity. Journal of Infectious Diseases, 2021, 223, 178-179.	4.0	24
16	A general strategy to inhibit serine protease by targeting its autolysis loop. FASEB Journal, 2021, 35, e21259.	0.5	14
17	Regulation of <scp>proâ€f^K</scp> activation: a key checkpoint in Bacillus subtilis sporulation. Environmental Microbiology, 2021, 23, 2366-2373.	3.8	7
18	Novel pH-Triggered Doxorubicin-Releasing Nanoparticles Self-Assembled by Functionalized Î²-Cyclodextrin and Amphiphilic Phthalocyanine for Anticancer Therapy. ACS Applied Materials & Interfaces, 2021, 13, 10674-10688.	8.0	33

#	Article	IF	Citations
19	Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discovery Today, 2021, 26, 1076-1085.	6.4	21
20	Synergy and allostery in ligand binding by HIV-1 Nef. Biochemical Journal, 2021, 478, 1525-1545.	3.7	4
21	Using porphyrins as albumin-binding molecules to enhance antitumor efficacies and reduce systemic toxicities of antimicrobial peptides. European Journal of Medicinal Chemistry, 2021, 217, 113382.	5.5	9
22	A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase. Journal of Controlled Release, 2021, 334, 153-163.	9.9	3
23	Development of a Potent Antimicrobial Peptide With Photodynamic Activity. Frontiers in Microbiology, 2021, 12, 624465.	3.5	5
24	Unveiling the molecular mechanism of pH-dependent interactions of human serum albumin with chemotherapeutic agent doxorubicin: A combined spectroscopic and constant-pH molecular dynamics study. Journal of Molecular Liquids, 2021, 333, 115949.	4.9	9
25	Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. Journal of Virology, 2021, 95, e0086121.	3.4	24
26	Dual effects of quercetin on protein digestion and absorption in the digestive tract. Food Chemistry, 2021, 358, 129891.	8.2	13
27	Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds. Dyes and Pigments, 2021, 194, 109570.	3.7	12
28	Effects of hydroxyl radicals produced by a zinc phthalocyanine photosensitizer on tumor DNA. Dyes and Pigments, 2020, 173, 107894.	3.7	10
29	Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel. ACS Applied Materials & Interfaces, 2020, 12, 4221-4230.	8.0	13
30	A nanometer-sized protease inhibitor for precise cancer diagnosis and treatment. Journal of Materials Chemistry B, 2020, 8, 504-514.	5.8	6
31	Photo-triggered release of doxorubicin from liposomes formulated by amphiphilic phthalocyanines for combination therapy to enhance antitumor efficacy. Journal of Materials Chemistry B, 2020, 8, 8022-8036.	5.8	15
32	Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis. Biomedicine and Pharmacotherapy, 2020, 130, 110528.	5.6	12
33	Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a. Life Sciences, 2020, 246, 117404.	4.3	6
34	Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA. RSC Advances, 2020, 10, 34517-34526.	3.6	21
35	Inhibition of the Citrus Canker Pathogen Using a Photosensitizer Assisted by Sunlight Irradiation. Frontiers in Microbiology, 2020, 11, 571691.	3.5	7
36	Suppression of cancer proliferation and metastasis by a versatile nanomedicine integrating photodynamic therapy, photothermal therapy, and enzyme inhibition. Acta Biomaterialia, 2020, 113, 541-553.	8.3	8

#	Article	IF	Citations
37	Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/Î±-neurotoxin Domain. International Journal of Biological Sciences, 2020, 16, 981-993.	6.4	4
38	Therapeutics targeting the fibrinolytic system. Experimental and Molecular Medicine, 2020, 52, 367-379.	7.7	73
39	Naftifine enhances photodynamic therapy against Staphylococcus aureus by inhibiting staphyloxanthin expression. Dyes and Pigments, 2020, 179, 108392.	3.7	8
40	Photocyanine: A novel and effective phthalocyanine-based photosensitizer for cancer treatment. Journal of Innovative Optical Health Sciences, 2020, 13, .	1.0	26
41	Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases. Bioscience, Biotechnology and Biochemistry, 2020, 84, 1153-1159.	1.3	1
42	Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy . International Journal of Nanomedicine, 2020, Volume 15, 151-167.	6.7	9
43	Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells. Experimental Cell Research, 2020, 391, 111987.	2.6	8
44	Plasma levels of the active form of suPAR are associated with COVID-19 severity. Critical Care, 2020, 24, 704.	5.8	24
45	Small Peptides as Modulators of Serine Proteases. Current Medicinal Chemistry, 2020, 27, 3686-3705.	2.4	6
46	A series of photosensitizers with incremental positive electric charges for photodynamic antitumor therapy. RSC Advances, 2019, 9, 24560-24567.	3.6	6
47	Solution Structure of SpoIVB Reveals Mechanism of PDZ Domain-Regulated Protease Activity. Frontiers in Microbiology, 2019, 10, 1232.	3.5	3
48	Structural basis of sequence-specific Holliday junction cleavage by MOC1. Nature Chemical Biology, 2019, 15, 1241-1248.	8.0	21
49	Crystal structure, epitope, and functional impact of an antibody against a superactive FVII a provide insights into allosteric mechanism. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 412-419.	2.3	0
50	6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126753.	2.2	21
51	Tumor-targeting photodynamic therapy based on folate-modified polydopamine nanoparticles . International Journal of Nanomedicine, 2019, Volume 14, 6799-6812.	6.7	32
52	Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors. Cancer and Metastasis Reviews, 2019, 38, 507-524.	5.9	14
53	Suppression of Tumor Growth and Metastases by Targeted Intervention in Urokinase Activity with Cyclic Peptides. Journal of Medicinal Chemistry, 2019, 62, 2172-2183.	6.4	12
54	A novel ELISA for the detection of active form of plasminogen activator inhibitor-1 based on a highly specific trapping agent. Analytica Chimica Acta, 2019, 1053, 98-104.	5.4	8

#	Article	IF	Citations
55	Expression and purification of recombinant serine protease domain of human coagulation factor XII in Pichia pastoris. Bioscience, Biotechnology and Biochemistry, 2019, 83, 1815-1821.	1.3	6
56	Composite of silver nanoparticles and photosensitizer leads to mutual enhancement of antimicrobial efficacy and promotes wound healing. Chemical Engineering Journal, 2019, 374, 1373-1381.	12.7	61
57	Crystal structure of the unoccupied murine urokinaseâ€type plasminogen activator receptor (<scp>uPAR</scp>) reveals a tightly packed DIIâ€"DIII unit. FEBS Letters, 2019, 593, 1236-1247.	2.8	4
58	Structural determination of group A Streptococcal surface dehydrogenase and characterization of its interaction with urokinase-type plasminogen activator receptor. Biochemical and Biophysical Research Communications, 2019, 510, 539-544.	2.1	0
59	Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release. Theranostics, 2019, 9, 884-899.	10.0	23
60	tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity. Thrombosis and Haemostasis, 2019, 119, 077-086.	3.4	8
61	An efficient synergistic cancer therapy by integrating cell cycle inhibitor and photosensitizer into polydopamine nanoparticles. Journal of Materials Chemistry B, 2018, 6, 2620-2629.	5.8	16
62	A novel purification procedure for recombinant human serum albumin expressed in Pichia pastoris. Protein Expression and Purification, 2018, 149, 37-42.	1.3	10
63	Smart Photosensitizer: Tumor-Triggered Oncotherapy by Self-Assembly Photodynamic Nanodots. ACS Applied Materials & Interfaces, 2018, 10, 15369-15380.	8.0	34
64	Probing the interactions of phthalocyanine-based photosensitizers with model phospholipid bilayer by molecular dynamics simulations. Journal of Porphyrins and Phthalocyanines, 2018, 22, 764-770.	0.8	13
65	The CD163 long-range scavenger receptor cysteine-rich repeat: expression, purification and X-ray crystallographic characterization. Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 322-326.	0.8	3
66	Novel pH-sensitive zinc phthalocyanine assembled with albumin for tumor targeting and treatment. International Journal of Nanomedicine, 2018, Volume 13, 7681-7695.	6.7	17
67	Enhanced anti-microbial effect through cationization of a mono-triazatricyclodecane substituted asymmetric phthalocyanine. Journal of Inorganic Biochemistry, 2018, 189, 192-198.	3.5	13
68	Phthalocyanine-based photosensitizer with tumor-pH-responsive properties for cancer theranostics. Journal of Materials Chemistry B, 2018, 6, 6080-6088.	5.8	20
69	Insights into the binding mechanism of BODIPY-based photosensitizers to human serum albumin: A combined experimental and computational study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2018, 203, 158-165.	3.9	12
70	Near-infrared-triggered antibacterial and antifungal photodynamic therapy based on lanthanide-doped upconversion nanoparticles. Nanoscale, 2018, 10, 15485-15495.	5.6	90
71	Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 2017-2023.	2.4	3
72	Household light source for potent photo-dynamic antimicrobial effect and wound healing in an infective animal model. Biomedical Optics Express, 2018, 9, 1006.	2.9	17

#	Article	IF	Citations
73	Dissociation of zinc phthalocyanine aggregation on bacterial surface is key for photodynamic antimicrobial effect. Journal of Porphyrins and Phthalocyanines, 2018, 22, 925-934.	0.8	23
74	Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217. FEBS Letters, 2018, 592, 2658-2667.	2.8	5
75	Molecular basis of rutin inhibition of protein disulfide isomerase (PDI) by combinedin silicoand experimental methods. RSC Advances, 2018, 8, 18480-18491.	3.6	22
76	6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. Journal of Medicinal Chemistry, 2018, 61, 8299-8320.	6.4	56
77	Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. RSC Advances, 2018, 8, 28189-28197.	3.6	12
78	Dual antimicrobial actions on modified fabric leads to inactivation of drug-resistant bacteria. Dyes and Pigments, 2017, 140, 236-243.	3.7	28
79	Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Proteinâ€"Protein Interaction. Biochemistry, 2017, 56, 1768-1784.	2.5	17
80	Rapid killing of bacteria by a new type of photosensitizer. Applied Microbiology and Biotechnology, 2017, 101, 4691-4700.	3.6	39
81	Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator. Scientific Reports, 2017, 7, 3385.	3.3	27
82	An effective zinc phthalocyanine derivative against multidrug-resistant bacterial infection. Journal of Porphyrins and Phthalocyanines, 2017, 21, 205-210.	0.8	10
83	A structural mechanism of flavonoids in inhibiting serine proteases. Food and Function, 2017, 8, 2437-2443.	4.6	46
84	The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition. Journal of Biological Chemistry, 2017, 292, 8412-8423.	3.4	10
85	Recombinant hepatocyte growth factor activator inhibitor 1: expression inDrosophilaS2 cells, purification and crystallization. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 45-50.	0.8	1
86	Photodynamic Oncotherapy Mediated by Gonadotropin-Releasing Hormone Receptors. Journal of Medicinal Chemistry, 2017, 60, 8667-8672.	6.4	15
87	Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor. Acta Crystallographica Section F, Structural Biology Communications, 2017, 73, 486-490.	0.8	1
88	A Molecular Combination of Zinc(II) Phthalocyanine and Tamoxifen Derivative for Dual Targeting Photodynamic Therapy and Hormone Therapy. Journal of Medicinal Chemistry, 2017, 60, 6693-6703.	6.4	60
89	The Crystal Structure of the Fifth Scavenger Receptor Cysteine-Rich Domain of Porcine CD163 Reveals an Important Residue Involved in Porcine Reproductive and Respiratory Syndrome Virus Infection. Journal of Virology, 2017, 91, .	3.4	58
90	A Perspective on Reagent Diversity and Non-covalent Binding of Reactive Carbonyl Species (RCS) and Effector Reagents in Non-enzymatic Glycation (NEG): Mechanistic Considerations and Implications for Future Research. Frontiers in Chemistry, 2017, 5, 39.	3.6	8

#	Article	IF	Citations
91	A long-acting PAI-1 inhibitor reduces thrombus formation. Thrombosis and Haemostasis, 2017, 117, 1338-1347.	3.4	22
92	Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors. International Journal of Biological Sciences, 2017, 13, 1222-1233.	6.4	10
93	Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials. Nanotheranostics, 2017, 1, 346-357.	5.2	76
94	13 Tumor-specific imaging and photodynamic therapy targeting the urokinase receptor. Series in Cellular and Clinical Imaging, 2017, , 259-274.	0.2	0
95	A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior. Journal of Biological Chemistry, 2016, 291, 15156-15168.	3.4	32
96	Reâ€engineering the Immune Response to Metastatic Cancer: Antibodyâ€Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie - International Edition, 2016, 55, 3642-3646.	13.8	63
97	An ELISA method detecting the active form of suPAR. Talanta, 2016, 160, 205-210.	5.5	8
98	A substrate-driven allosteric switch that enhances PDI catalytic activity. Nature Communications, 2016, 7, 12579.	12.8	98
99	Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding. Biochemical Journal, 2016, 473, 2359-2368.	3.7	12
100	A specific plasminogen activator inhibitorâ€1 antagonist derived from inactivated urokinase. Journal of Cellular and Molecular Medicine, 2016, 20, 1851-1860.	3.6	23
101	Reâ€engineering the Immune Response to Metastatic Cancer: Antibodyâ€Recruiting Small Molecules Targeting the Urokinase Receptor. Angewandte Chemie, 2016, 128, 3706-3710.	2.0	23
102	Dimer conformation of soluble PECAM-1, an endothelial marker. International Journal of Biochemistry and Cell Biology, 2016, 77, 102-108.	2.8	11
103	Sub-5 nm lanthanide-doped lutetium oxyfluoride nanoprobes for ultrasensitive detection of prostate specific antigen. Chemical Science, 2016, 7, 2572-2578.	7.4	71
104	Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 599-606.	2.4	6
105	Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. Data in Brief, 2016, 6, 550-555.	1.0	2
106	Photodynamic antimicrobial chemotherapy using zinc phthalocyanine derivatives in treatment of bacterial skin infection. Journal of Biomedical Optics, 2016, 21, 018001.	2.6	24
107	Both platelet- and endothelial cellâ€“derived ERp5 support thrombus formation in a laser-induced mouse model of thrombosis. Blood, 2015, 125, 2276-2285.	1.4	59
108	Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood, 2015, 125, 1976-1985.	1.4	71

#	Article	IF	Citations
109	Multifunctional Nanoâ€Bioprobes Based on Rattleâ€Structured Upconverting Luminescent Nanoparticles. Angewandte Chemie, 2015, 127, 8026-8030.	2.0	14
110	Multifunctional Nanoâ€Bioprobes Based on Rattleâ€Structured Upconverting Luminescent Nanoparticles. Angewandte Chemie - International Edition, 2015, 54, 7915-7919.	13.8	145
111	Interpreted Recognition Process: A Highly Sensitive and Selective Luminescence Chemosensor. Chemistry - A European Journal, 2015, 21, 11767-11772.	3.3	20
112	Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. International Journal of Nanomedicine, 2015, 10, 5327.	6.7	17
113	Phthalocyanine-Biomolecule Conjugated Photosensitizers for Targeted Photodynamic Therapy and Imaging. Current Drug Metabolism, 2015, 16, 816-832.	1.2	30
114	Design of Specific Serine Protease Inhibitors Based on a Versatile Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 8868-8876.	6.4	16
115	Expression and crystallographic studies of the ligand-binding region of the human endocytic collagen receptor uPARAP. Acta Crystallographica Section F, Structural Biology Communications, 2015, 71, 1442-1447.	0.8	2
116	Heavy atom enhanced generation of singlet oxygen in novel indenofluorene-based two-photon absorbing chromophores for photodynamic therapy. Dyes and Pigments, 2015, 117, 7-15.	3.7	21
117	Stabilizing a Flexible Interdomain Hinge Region Harboring the SMB Binding Site Drives uPAR into Its Closed Conformation. Journal of Molecular Biology, 2015, 427, 1389-1403.	4.2	25
118	Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its bâ€²x Domain. Journal of Biological Chemistry, 2015, 290, 23543-23552.	3.4	90
119	Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues. International Journal of Biochemistry and Cell Biology, 2015, 62, 88-92.	2.8	2
120	Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1. Journal of Biological Chemistry, 2015, 290, 25795-25804.	3.4	41
121	Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. Data in Brief, 2015, 5, 107-113.	1.0	13
122	A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging. Acta Biomaterialia, 2015, 23, 116-126.	8.3	16
123	Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptideâ€“Protease Fusions. Journal of Molecular Biology, 2015, 427, 3110-3122.	4.2	9
124	Lanthanide-doped luminescent nano-bioprobes for the detection of tumor markers. Nanoscale, 2015, 7, 4274-4290.	5.6	101
125	Spatioselective Fabrication of Highly Effective Antibacterial Layer by Surfaceâ€Anchored Discrete Metalâ€“Organic Frameworks. Advanced Materials Interfaces, 2015, 2, 1400405.	3.7	23
126	Structure and Enzymatic Activities of Human Serum Albumin. Current Pharmaceutical Design, 2015, 21, 1831-1836.	1.9	29

#	Article	IF	Citations
127	A Novel Tumor Targeting Drug Carrier for Optical Imaging and Therapy. Theranostics, 2014, 4, 642-659.	10.0	61
128	Photodynamic antimicrobial chemotherapy using zinc phthalocyanine derivative for bacterial skin infection. Proceedings of SPIE, 2014, , .	0.8	0
129	A Cyclic Peptidic Serine Protease Inhibitor: Increasing Affinity by Increasing Peptide Flexibility. PLoS ONE, 2014, 9, e115872.	2.5	22
130	An effective zinc phthalocyanine derivative for photodynamic antimicrobial chemotherapy. Journal of Luminescence, 2014, 152, 103-107.	3.1	40
131	Design, synthesis, and SAR of embelin analogues as the inhibitors of PAI-1 (plasminogen activator) Tj ETQq1 1 0.784314 rgBT /Overlo	2.2	10
132	Evaluation of Interactions between Urokinase Plasminogen and Inhibitors Using Molecular Dynamic Simulation and Free-Energy Calculation. Journal of Physical Chemistry A, 2014, 118, 9113-9119.	2.5	13
133	Lanthanide-doped upconversion nanoparticles electrostatically coupled with photosensitizers for near-infrared-triggered photodynamic therapy. Nanoscale, 2014, 6, 8274.	5.6	133
134	Lanthanideâ€Doped LiLuF₄ Upconversion Nanoprobes for the Detection of Disease Biomarkers. Angewandte Chemie - International Edition, 2014, 53, 1252-1257.	13.8	397
135	Zinc phthalocyanine conjugated with the amino-terminal fragment of urokinase for tumor-targeting photodynamic therapy. Acta Biomaterialia, 2014, 10, 4257-4268.	8.3	54
136	Dissolutionâ€Enhanced Luminescent Bioassay Based on Inorganic Lanthanide Nanoparticles. Angewandte Chemie - International Edition, 2014, 53, 12498-12502.	13.8	48
137	ML359, a Small Molecule Inhibitor of Protein Disulfide Isomerase That Prevents Thrombus Formation and Inhibits Oxidoreductase but Not Transnitrosylase Activity. Blood, 2014, 124, 2880-2880.	1.4	2
138	Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (Î±M). PLoS ONE, 2014, 9, e85349.	2.5	34
139	Regulation of Protein Disulfide Isomerase By S-Nitrosylation Controls Its Function during Thrombus Formation. Blood, 2014, 124, 93-93.	1.4	0
140	Structural Mechanism of Ring-opening Reaction of Glucose by Human Serum Albumin. Journal of Biological Chemistry, 2013, 288, 15980-15987.	3.4	105
141	Structural Insight into Inactivation of Plasminogen Activator Inhibitor-1 by a Small-Molecule Antagonist. Chemistry and Biology, 2013, 20, 253-261.	6.0	34
142	Lanthanide-doped NaScF4 nanoprobes: crystal structure, optical spectroscopy and biodetection. Nanoscale, 2013, 5, 6430.	5.6	74
143	Rezymogenation of active urokinase induced by an inhibitory antibody. Biochemical Journal, 2013, 449, 161-166.	3.7	25
144	Crystal Structures of Matriptase in Complex with Its Inhibitor Hepatocyte Growth Factor Activator Inhibitor-1. Journal of Biological Chemistry, 2013, 288, 11155-11164.	3.4	30

#	Article	IF	Citations
145	Bicyclic Peptide Inhibitor of Urokinaseâ€Type Plasminogen Activator: Mode of Action. ChemBioChem, 2013, 14, 2179-2188.	2.6	17
146	Subâ€10â€…nm Lanthanideâ€Doped CaF₂ Nanoprobes for Timeâ€Resolved Luminescent Biodetection. Angewandte Chemie - International Edition, 2013, 52, 6671-6676.	13.8	185
147	Detection of Active Matriptase Using a Biotinylated Chloromethyl Ketone Peptide. PLoS ONE, 2013, 8, e77146.	2.5	14
148	Urokinase-type Plasminogen Activator-like Proteases in Teleosts Lack Genuine Receptor-binding Epidermal Growth Factor-like Domains. Journal of Biological Chemistry, 2012, 287, 27526-27536.	3.4	8
149	Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of Î²3 integrins. Blood, 2012, 120, 647-655.	1.4	117
150	Structural Evidence of Perfluorooctane Sulfonate Transport by Human Serum Albumin. Chemical Research in Toxicology, 2012, 25, 990-992.	3.3	75
151	Amine-Functionalized Lanthanide-Doped Zirconia Nanoparticles: Optical Spectroscopy, Time-Resolved Fluorescence Resonance Energy Transfer Biodetection, and Targeted Imaging. Journal of the American Chemical Society, 2012, 134, 15083-15090.	13.7	221
152	Crystal Structure of the Urokinase Receptor in a Ligand-Free Form. Journal of Molecular Biology, 2012, 416, 629-641.	4.2	42
153	Amine-Functionalized Lanthanide-Doped KGdF₄ Nanocrystals as Potential Optical/Magnetic Multimodal Bioprobes. Journal of the American Chemical Society, 2012, 134, 1323-1330.	13.7	372
154	Enhanced Photodynamic Efficacy of Zinc Phthalocyanine by Conjugating to Heptalysine. Bioconjugate Chemistry, 2012, 23, 2168-2172.	3.6	45
155	Structural recognition mechanisms between human Src homology domain 3 (SH3) and ALGâ€2â€interacting protein X (Alix). FEBS Letters, 2012, 586, 1759-1764.	2.8	9
156	Receptor-Targeting Phthalocyanine Photosensitizer for Improving Antitumor Photocytotoxicity. PLoS ONE, 2012, 7, e37051.	2.5	32
157	The Binding Mechanism of a Peptidic Cyclic Serine Protease Inhibitor. Journal of Molecular Biology, 2011, 412, 235-250.	4.2	16
158	Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. Biochemical Journal, 2011, 438, 39-51.	3.7	14
159	Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1. BMC Structural Biology, 2011, 11, 30.	2.3	51
160	A fluorescent fatty acid probe, DAUDA, selectively displaces two myristates bound in human serum albumin. Protein Science, 2011, 20, 2095-2101.	7.6	15
161	A New Type of Dyeâ€Sensitized Solar Cell with a Multilayered Photoanode Prepared by a Filmâ€Transfer Technique. Advanced Materials, 2011, 23, 2764-2768.	21.0	80
162	Substituted zinc phthalocyanine as an antimicrobial photosensitizer for periodontitis treatment. Journal of Porphyrins and Phthalocyanines, 2011, 15, 293-299.	0.8	35

#	Article	IF	Citations
163	Structural Basis for Therapeutic Intervention of uPA/uPAR System. Current Drug Targets, 2011, 12, 1729-1743.	2.1	33
164	Elucidation of the Contribution of Active Site and Exosite Interactions to Affinity and Specificity of Peptidylic Serine Protease Inhibitors Using Non-Natural Arginine Analogs. Molecular Pharmacology, 2011, 80, 585-597.	2.3	21
165	Mimicry of the Regulatory Role of Urokinase in Lamellipodia Formation by Introduction of a Non-native Interdomain Disulfide Bond in Its Receptor. Journal of Biological Chemistry, 2011, 286, 43515-43526.	3.4	28
166	Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1. Journal of Biological Chemistry, 2011, 286, 7027-7032.	3.4	58
167	Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain 3 and ALG-2-interacting protein X. Biochemical Journal, 2010, 431, 93-102.	3.7	9
168	Pentalysine Î²â€Carbonylphthalocyanine Zinc: An Effective Tumorâ€Targeting Photosensitizer for Photodynamic Therapy. ChemMedChem, 2010, 5, 890-898.	3.2	40
169	Crystal structure of a triacylglycerol lipase from Penicillium expansum at 1.3 Ã... determined by sulfur SAD. Proteins: Structure, Function and Bioinformatics, 2010, 78, 1601-1605.	2.6	16
170	Structure-based Engineering of Species Selectivity in the Interaction between Urokinase and Its Receptor. Journal of Biological Chemistry, 2010, 285, 10982-10992.	3.4	68
171	Trp2313-His2315 of Factor VIII C2 Domain Is Involved in Membrane Binding. Journal of Biological Chemistry, 2010, 285, 8824-8829.	3.4	39
172	Expression, purification and characterization of recombinant Jerdonitin, a P-II class snake venom metalloproteinase comprising metalloproteinase and disintegrin domains. Toxicon, 2010, 55, 375-380.	1.6	16
173	Structural basis of transport of lysophospholipids by human serum albumin. Biochemical Journal, 2009, 423, 23-30.	3.7	43
174	Challenges for Drug Discovery - A Case Study of Urokinase Receptor Inhibition. Combinatorial Chemistry and High Throughput Screening, 2009, 12, 961-967.	1.1	11
175	Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nature Structural and Molecular Biology, 2008, 15, 422-423.	8.2	103
176	Crystal Structure of Human Factor VIII: Implications for the Formation of the Factor IXa-Factor VIIIa Complex. Structure, 2008, 16, 597-606.	3.3	209
177	A new drug binding subsite on human serum albumin and drugâ€“drug interaction studied by X-ray crystallography. Journal of Structural Biology, 2008, 162, 40-49.	2.8	114
178	Effect of human serum albumin on drug metabolism: Structural evidence of esterase activity of human serum albumin. Journal of Structural Biology, 2007, 157, 348-355.	2.8	184
179	Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. Journal of Structural Biology, 2007, 160, 1-10.	2.8	52
180	An Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibody: Crystal Structure and Binding Epitope. Journal of Molecular Biology, 2007, 365, 1117-1129.	4.2	19

#	Article	IF	Citations
181	Crystal Structure of the Bovine Lactadherin C2 Domain, a Membrane Binding Motif, Shows Similarity to the C2 Domains of Factor V and Factor VIII. Journal of Molecular Biology, 2007, 371, 717-724.	4.2	44
182	X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein. BMC Structural Biology, 2007, 7, 29.	2.3	17
183	An open conformation of switch I revealed by Sar1-GDP crystal structure at low Mg2+. Biochemical and Biophysical Research Communications, 2006, 348, 908-915.	2.1	14
184	Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. Protein Expression and Purification, 2006, 49, 71-77.	1.3	11
185	Derivatizable phthalocyanine with single carboxyl group: Synthesis and purification. Inorganic Chemistry Communication, 2006, 9, 313-315.	3.9	80
186	Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor. Science, 2006, 311, 656-659.	12.6	273
187	Crystal Structure of the Bovine Lactadherin C2 Domain, a Potential Anticoagulant, Shows Similarity to Factor V and Factor VIII.. Blood, 2006, 108, 194-194.	1.4	0
188	Purification and preliminary crystallographic analysis of a Penicillium expansum lipase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1752, 99-102.	2.3	13
189	Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1â€“143). Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 697-700.	2.5	20
190	Optimization of Crystals of an Inhibitory Antibody of Urokinase Plasminogen Activator Receptor (uPAR) with Hydrogen Peroxide and Low Protein Concentration. Protein and Peptide Letters, 2005, 12, 655-658.	0.9	1
191	Crystal Structure of the Calcium-stabilized Human Factor IX Gla Domain Bound to a Conformation-specific Anti-factor IX Antibody. Journal of Biological Chemistry, 2004, 279, 14338-14346.	3.4	64
192	Structural basis of membrane binding by Gla domains of vitamin Kâ€“dependent proteins. Nature Structural and Molecular Biology, 2003, 10, 751-756.	8.2	207
193	Protein engineering for crystallization of the GTPase Sar1 that regulates ER vesicle budding. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 700-703.	2.5	2
194	Crystal structure of Sar1-GDP at 1.7 AÌŠ resolution and the role of the NH2 terminus in ER export. Journal of Cell Biology, 2001, 155, 937-948.	5.2	149
195	Novel Interactions between Urokinase and Its Receptor. Journal of Biological Chemistry, 2000, 275, 24304-24312.	3.4	32
196	Roles for glycosylation of cell surface receptors involved in cellular immune recognition. Journal of Molecular Biology, 1999, 293, 351-366.	4.2	221
197	The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab 5G9 and TFÂ·5G9 complex 1 1Edited by D. C. Rees. Journal of Molecular Biology, 1998, 275, 873-894.	4.2	113
198	Structural Basis of Plasticity in T Cell Receptor Recognition of a Self Peptide-MHC Antigen. Science, 1998, 279, 1166-1172.	12.6	641